Insights

Strategic Acquisition Kineta is transitioning through a major acquisition by TuHURA Biosciences, which indicates a consolidated immuno-oncology platform and potential cross-sell of Kineta's VISTA targeting assets to TuHURA’s existing pipeline.

Phase 2 Readiness Kineta owns KVA12123 (VISTA inhibitor) with Phase 2 readiness and data presented at AACR; opportunity to position complementary development services, partnering discussions, or co-development options with TuHURA’s Phase 3 pipeline.

Clinical Expertise Strong emphasis on VISTA pathway modulation and anti-PD-1 resistance settings in melanoma; potential to offer collaboration on translational studies, biomarker development, or GMP-grade manufacturing support for immunotherapy candidates.

Pipeline Synergy TuHURA’s interest in combining KVA12123 with IFx-Hu2.0 suggests sales avenues in combination therapy development, assay collaboration, and access to Kineta’s preclinical/clinical data for strategic market positioning.

Funding & Growth Significant funding activity and completed mergers indicate an environment favorable for partnered financing, joint ventures, and equity-backed collaborations to accelerate late-stage immuno-oncology programs.

Similar companies to Kineta

Kineta Tech Stack

Kineta uses 8 technology products and services including WordPress, CookieYes, NetSuite, and more. Explore Kineta's tech stack below.

Media & News

Kineta's Email Address Formats

Kineta uses at least 6 email formats:
Kineta Email FormatsExamplePercentage
FLast@kinetabio.comJDoe@kinetabio.com
94%
First@kinetabio.comJohn@kinetabio.com
4%
FirstLast@kinetabio.comJohnDoe@kinetabio.com
2%
FLast@kineta.usJDoe@kineta.us
90%
First@kineta.usJohn@kineta.us
5%
LFirst@kineta.usDJohn@kineta.us
5%

Frequently Asked Questions

What is Kineta's phone number?

Minus sign iconPlus sign icon
You can contact Kineta's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Kineta's stock symbol?

Minus sign iconPlus sign icon
Kineta is a publicly traded company; the company's stock symbol is KA.

What is Kineta's official website and social media links?

Minus sign iconPlus sign icon
Kineta's official website is kinetabio.com and has social profiles on LinkedIn.

How much revenue does Kineta generate?

Minus sign iconPlus sign icon
As of October 2026, Kineta's annual revenue is estimated to be $10M - $25M.

What is Kineta's SIC code and NAICS code?

Minus sign iconPlus sign icon
Kineta's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Kineta have currently?

Minus sign iconPlus sign icon
As of October 2026, Kineta has approximately 32 employees across 3 continents, including North America, Asia and South America. Key team members include Vice President Of Business Development: B. J., Senior Vice President Capital Acquisition: R. H. and Director: K. W. O. Explore Kineta's employee directory with LeadIQ.

What industry does Kineta belong to?

Minus sign iconPlus sign icon
Kineta operates in the Biotechnology Research industry.

What technology does Kineta use?

Minus sign iconPlus sign icon
Kineta's tech stack includes WordPress, CookieYes, NetSuite, Shopify, Microsoft 365, Headroom.js, Bootstrap and Twitter.

What is Kineta's email format?

Minus sign iconPlus sign icon
Kineta's email format typically follows the pattern of FLast@kinetabio.com. Find more Kineta email formats with LeadIQ.

How much funding has Kineta raised to date?

Minus sign iconPlus sign icon
As of October 2026, Kineta has raised $98M in funding. The last funding round occurred on Oct 04, 2023.

When was Kineta founded?

Minus sign iconPlus sign icon
Kineta was founded in 2008.
Kineta logo

Kineta

Biotechnology ResearchWashington, United States11-50 Employees

Kineta is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology to address cancer immune resistance. The company is based in Seattle, Washington, United States, and employs between 11 and 50 people. It operates in the biotechnology research industry and maintains a website at https://kinetabio.com. Kineta has developed a VISTA-targeting monoclonal antibody program, including candidates such as KVA12123 (also referred to as KVA1213 in some sources), which has been studied in early-phase clinical settings. In June 2025, TuHURA Biosciences completed the acquisition of Kineta, with Kineta’s antibody asset renamed TBS-2025 as part of TuHURA’s late-stage immuno-oncology pipeline.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
KA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
11-50

Section iconFunding & Financials

  • $98M

    Kineta has raised a total of $98M of funding over 21 rounds. Their latest funding round was raised on Oct 04, 2023 as a Post IPO Equity.

  • $10M - $25M

    Kineta's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.